Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prevention and treatment of hypokalemia,Replacement of potassium, fluid, and electrolytes in patients requiring intravenous therapy
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Not applicable for endogenous potassium; infused potassium distributes with a rapid initial phase (~1 h) and a slower terminal phase (~8-12 h) reflecting cellular equilibration
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Potassium is not metabolized; it is excreted renally. Dextrose is metabolized to carbon dioxide and water via glycolysis and oxidative phosphorylation. Sodium and chloride are excreted renally.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >90% as potassium ion; minor fecal loss <10%
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Minimal; <5%
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.2-0.5 L/kg, reflecting extracellular and intracellular distribution
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: ~90% (well absorbed); IV: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR 10-50 m L/min: use with caution, monitor potassium levels closely; GFR <10 m L/min: avoid use or reduce dose to prevent hyperkalemia. Potassium supplementation is generally not recommended in severe renal impairment unless documented hypokalemia.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dosing adjustment required for Child-Pugh class A, B, or C. Monitor serum potassium as hepatic impairment may affect acid-base balance.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Dose determined by age, weight, and serum potassium; typical infusion rate: 0.5-1 m Eq/kg over 1 hour; maximum daily dose: 3 m Eq/kg/day; maximum infusion rate: 1 m Eq/kg/hour. Use in children only if hypokalemia is documented and monitored.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to age-related decline in renal function; monitor renal function and serum potassium; consider lower initial doses and slower infusion rates (e.g., 5-10 m Eq/hour).
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
NO BLACK BOX WARNINGS FOR THIS PRODUCT.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Administration may cause hyperkalemia, especially in patients with renal impairment, or with rapid infusion.,Use with caution in patients with cardiac disease, conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, acidosis), or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs.,Monitor serum potassium, glucose, and electrolytes regularly.,Do not administer unless solution is clear and container is intact.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Renal failure (severe or anuria),Severe metabolic acidosis,Concurrent use of potassium-sparing diuretics or potassium supplements (unless closely monitored),Addison's disease
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados) and potassium-containing salt substitutes while receiving this infusion, unless specifically instructed by your physician. Also, limit sodium intake if hypertensive or edematous.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia, hypernatremia) can adversely affect the fetus. Use only if clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Potassium, dextrose, and sodium are normal components of breast milk. Potassium chloride and sodium chloride are excreted into breast milk but are not expected to cause adverse effects in nursing infants. No M/P ratio is available; however, these substances are naturally present. Use with caution only if clearly needed.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No standard dose adjustment required; pregnancy does not significantly alter pharmacokinetics of potassium, dextrose, or sodium. Dose based on individual electrolyte and fluid needs, with careful monitoring to avoid maternal electrolyte disturbances that could affect the fetus.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor serum potassium and glucose levels during infusion, especially in renal impairment or diabetic patients. Use with caution in patients on digoxin, as hyperkalemia can precipitate digoxin toxicity. Do not administer concentrated potassium solutions peripherally; typical maximum peripheral concentration is 10 m Eq/100 m L. Check for vein irritation or phlebitis at infusion site. Use a volumetric pump to control infusion rate; rapid infusion can cause cardiac arrest.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication contains potassium, dextrose (sugar), and sodium chloride (salt), administered intravenously to replenish electrolytes and provide calories.,Tell your healthcare provider if you have kidney disease, heart problems, diabetes, or are on medications such as ACE inhibitors, ARBs, or potassium-sparing diuretics.,Report any symptoms of high potassium (muscle weakness, irregular heartbeat, tingling) or high blood sugar (increased thirst, frequent urination, confusion) immediately.,Do not consume potassium-rich foods or salt substitutes without consulting your doctor, as this may increase the risk of hyperkalemia.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it is essential for maintenance of membrane potential, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Dextrose provides calories and may decrease protein catabolism. Sodium chloride helps maintain extracellular fluid volume and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by serum potassium levels and patient condition; typical maintenance: 10-20 m Eq potassium per hour; maximum infusion rate: 20 m Eq/hour (not to exceed 1 m Eq/kg/hour); concentration not to exceed 80 m Eq/L via peripheral line. Each 1 L of this product contains 5 m Eq potassium chloride, 50 g dextrose, and 77 m Eq sodium chloride.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are not teratogenic. There is no evidence of fetal risk from electrolyte and fluid administration at recommended doses. However, m. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.